Mesoblast’s Revascor Gains FDA Designation Boost

Mesoblast (MESO) has released an update.

Mesoblast Limited has announced that its stromal cell therapy, Revascor, has been granted Regenerative Medicine Advanced Therapy designation by the FDA for use in children with congenital heart disease, following promising trial results. This designation, alongside previously granted Rare Pediatric Disease and Orphan-Drug Designations, could expedite the development and potential approval of Revascor, creating significant interest in Mesoblast’s market prospects. With the therapy showing significant clinical benefits, investors might see potential growth opportunities as Mesoblast advances its innovative treatments in the healthcare sector.

For further insights into MESO stock, check out TipRanks’ Stock Analysis page.